Impact of oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation

Breast Journal

Volumn 19, Issue 3, 2013, Pages 269-275

  Biroschak, Julianne R ^a   Schwartz, Gordon F ^b   Palazzo, Juan P ^b   Toll, Adam D ^c   Brill, Kristin L ^d   Jaslow, Rebecca J ^b   Lee, Sun Yong ^e  

^a GEORGE WASHINGTON UNIVERSITY HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^e Aria Health   (United States)

Author keywords

breast cancer; gene analysis; Oncotype Dx

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ASSAY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; DECISION MAKING; GENE EXPRESSION PROFILING; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE NEGATIVE EARLY BREAST CANCER; ONCOTYPE DX; PHYSICIAN; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SURGEON; VIGNETTE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84876789361     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12099     Document Type: Review

References (27)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Jatoi I, Chen BE, Anderson WF, Rosenberg PS,. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007; 25: 1683-90.
3. Berry DA, Cronin KA, Plevritis SK, et al,. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-92.
4. NCI Alert on Node-negative breast cancer. Breast cancer research and treatment. Breast Cancer Res Treat 1988; 12: 3-5.
5. Fisher B, Jeong JH, Bryant J, et al,. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858-68.
6. National Comprehensive Cancer Network (2007). NCCN Practice Guidelines in Oncology, Breast Cancer. Version 2.2011. Available at: http://www.nccn.org/ professionals/physician-gls/pdf/breast.pdf (accessed March 6, 2011).
7. Harris L, Fritshe H, Mennel R, et al,. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
8. Paik S, Shak S, Tang G, et al,. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
9. Paik S, Tang G, Shak S, et al,. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-34.
10. Habel LA, Shak S, Jacobs MK, et al,. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8: R25.
11. Dowsett M, Cuzick J, Wale C, et al,. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrazole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28: 1829-34.
12. Toi M, Iwata H, Yamanaka T, et al,. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 2010; 116: 3112-8.
13. Mamounas EP, Tang G, Fisher B, et al,. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results From NSABP B-14 and NSABP B-20. J Clin Oncol 2010; 28: 1677-83.
14. Esteva FJ, Sahin AA, Cristofanilli M, et al,. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005; 6: 136-41.
15. Gnant M, Harbeck N, Thomssen C, St Gallen,. Summary of the concensus discussion. Breast Care 2011; 20: 1319-29.
16. National Cancer Institute (2006). Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial). Available at: http://www.cancer.gov/clinicaltrials/ECOG-PACCT-1#EntryCriteria-CDR0000472066 (accessed March 6, 2011).
17. Asad J, Jacobson AF, Estabrook A, et al,. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 2008; 196: 527-9.
18. Lo SS, Mumby PB, Norton J, et al,. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010; 28: 1671-6.
19. Oratz R, Dev P, Cohn AL, Sedlacek SM,. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 2007; 3: 182-6.
20. Rayhanabad JA, Difronzo LA, Haigh PI, Romero L,. Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm. Am Surg 2008; 74: 887-90.
21. Kelly CM, Krishnamurthy S, Bianchini G, et al,. Utility of Oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, Her2-Normal, Grade II, Lymph Node-Negative Breast Cancers. Cancer 2010; 116: 5161-7.
22. Lyman GH, Cosler LE, Kuderer NM, Hornberger J,. Impact of a 21-gene RT-PCR assay on treatment decisions in early-breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007; 109: 1011-8.
23. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R,. Histopathologic variables predict Oncotype DX Recurrence Score. Mod Pathol 2006; 21: 1255-61.
24. Wolf I, Ben-Baruch N, Shapira-Frommer R, et al,. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 2008; 112: 731-6.
25. Geradts J, Bean SM, Bentley RC, Barry WT,. The Oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 2010; 28: 969-77.
26. Auerbach J, Kim M, Fineberg S,. Can features evaluated in the routine pathologic assessment of the lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med 2010; 134: 1697-701.
27. Goldstein LJ, Gray R, Badve S, et al,. Prognostic utility of the 21-gene assay in hormone-receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26: 4063-71.